Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
Sanofi makes a pre-JP Morgan splash with Kymab
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
SITC 2020 – second chances for Merck & Co and Oncosec
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Vantage Esmo 2020 roundup
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
